EYPT
NASDAQ · Pharmaceuticals
Eyepoint Inc
$3.85
-0.14 (-3.51%)
Financial Highlights (FY 2026)
Revenue
34.83M
Net Income
-257,518,177
Gross Margin
93.4%
Profit Margin
-739.4%
Rev Growth
-8.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.4% | 93.4% | 35.0% | 35.0% |
| Operating Margin | -776.0% | -698.4% | 22.3% | 21.7% |
| Profit Margin | -739.4% | -702.5% | 24.9% | 20.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 34.83M | 38.20M | 211.34M | 213.20M |
| Gross Profit | 32.53M | 35.69M | 73.87M | 74.52M |
| Operating Income | -270,271,071 | -266,802,636 | 47.20M | 46.31M |
| Net Income | -257,518,177 | -254,213,402 | 52.60M | 44.43M |
| Gross Margin | 93.4% | 93.4% | 35.0% | 35.0% |
| Operating Margin | -776.0% | -698.4% | 22.3% | 21.7% |
| Profit Margin | -739.4% | -702.5% | 24.9% | 20.8% |
| Rev Growth | -8.8% | -8.8% | -6.2% | +21.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 107.95M | 96.71M |
| Total Equity | — | — | 420.20M | 423.48M |
| D/E Ratio | — | — | 0.26 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -267,691,393 | -278,936,956 | 60.54M | 58.90M |
| Free Cash Flow | — | — | 38.74M | 42.58M |